13F filer · CIK 1834239
EQT Fund Management S.a r.l.
LUXEMBOURG, N4 · filing since Q2 2022 · last filing Aug 13, 2026
Reported value
$862.6M
$-158.1M vs prior
Positions
5
New / sold out
0 / 0
Added / reduced
2 / 0
Turnover
0.0%
buys $19.3M · sells $0
Top-10 weight
100.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | OCULIS HOLDING AG | +1,050,000 | +17.8% | +$14.6M |
| Added | EVOMMUNE INC | +358,680 | +7.3% | +$4.8M |
Biggest sells vs Q1 2026
No reduced or sold positions this quarter.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | WAYSTAR HLDG CORPCOM | 24,879,437 | $510.8M | 59.21% |
| 2 | PHARVARIS N VCOM | 3,424,609 | $118.4M | 13.73% |
| 3 | OCULIS HOLDING AGORDINARY SHARES | 6,950,294 | $96.4M | 11.18% |
| 4 | EVOMMUNE INCCOM SHS | 5,288,313 | $70.3M | 8.15% |
| 5 | AGOMAB THERAPEUTICS NVSPONSORED ADS | 5,141,992 | $66.7M | 7.74% |